SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLogistics Dev Regulatory News (LDG)

Share Price Information for Logistics Dev (LDG)

Share Price is delayed by 15 minutes
Get Live Data
13.75    0.00 (0.00%)
Bid:
13.50
Ask:
14.00
Spread: 0.50 (3.704%)
Market Cap: £56.90m
LDG Live PriceLast checked at - London Stock Exchange

Intraday Logistics Dev Share Chart

Portfolio NAV Update

30 May 2025 07:00

RNS Number : 6936K
Logistics Development Group PLC
30 May 2025
Β 

30 May 2025

Β 

Logistics Development Group plc

Β 

("LDG" or the "Company")

Β 

Portfolio NAV Update

Β 

Β 

LDG today announces its quarterly portfolio data. As at 31 March 2025, LDG's unaudited estimated net asset value ("NAV") per share was Β£0.246 which reflects an increase of 10.25% compared to the prior period being 31 December 2024. Post the Tender Offer, with the subsequent cancellation of 110,526,315 Ordinary Shares, the unaudited estimated NAV was Β£0.261 on the same basis. The NAV, in respect of private investments, has been assessed and reported to the Board by the Company's investment manager, DBAY, who applies the International Private Equity and Venture Capital Valuation ("IPEV") Guidelines in its valuation practices.

Β 

Update on the Company's Investment Portfolio

Β 

Β 

Underlying Investment

LDG's economic interest % of the asset

LDG's % of portfolio Company held

Additions / divestments in the three-month period to 31 March 2025

Total Investment Cost

Revenue

Employees

Finsbury Food Group Ltd

(Private)

Β 

25.31%

27.54%

None

Β£14.2m

Β£452.4 m (June 2024)

c. 3,500

SQLI SA

(Private)

Β 

10.72%

11.10%

None

Β£13.3m

€247m (December 2024)

c. 2,300

Alliance Pharma plc

(Private)

Β 

13.16%

13.16%

None

Β£39.0m

Β£180.3m (December 2024)

c. 290

Other Minority Interests

1.46%

1.46%

Β£1.2m

Β£1.2m

N/A

N/A

Β 

Β 

LDG's investments are held through Fixtaia Limited, a wholly owned subsidiary.

Β 

Finsbury Food Group Ltd ("Finsbury")

Business description

For the year ended 29 June 2024 (being the latest audited period), Finsbury generated Β£452.4 million of revenue from its specialty bakery business, producing and selling high-quality bread and cakes to food retailers and food service clients across the UK and Europe. Its product portfolio consists largely of either essential bakery products (e.g. organic & artisan bread, buns and rolls) or highly emotional event purchases (e.g. brand-licensed celebration cakes for parties, especially for children).

Β 

Its largest retail bakery clients include supermarkets (e.g. Tesco, Co-op, Waitrose, Sainsbury's) and its largest food service clients include restaurants and coffee shops (e.g. KFC, Costa Coffee, Bidfood, Brakes). The company has longstanding relationships with many licensed brands, manufacturing quality bread and cakes for some of the biggest names in the market (e.g. Disney, Thorntons).

Finsbury operates in Europe via its Lightbody Europe subsidiary in France and Ultrapharm business in Poland. The company was incorporated in 1925, is based in Cardiff and has 3,500 employees.

Β 

Q1 Highlights

Β· In the third quarter of FY25 (year ending June 2025), Finsbury reported revenue of Β£111m, representing a Β£4m or 4% decline compared to the prior year. The drop was primarily due to the Easter holiday falling in the fourth quarter this year. Profitability benefited from price recovery net of cost inflation and continued efficiencies from the Operating Brilliance Programme.

Β· Full-year revenue is expected to decline modestly by 1% due to portfolio optimisation and softer volume growth, adjusting for these strategic changes reveals an underlying 1% year-on-year increase. This improvement supports further margin expansion.

Β· Finsbury continues to evaluate targeted acquisition opportunities within the sector as part of its broader value creation strategy.

Β 

SQLI SA ("SQLI")

Business description

SQLI is a pan-European IT services business with leading positions in the e-commerce / omnichannel integration and digital experience space. SQLI generated €247million revenue for the year ended 31 December 2024 (being the latest audited period). It is headquartered in Paris and its 2,300 employees are spread over 13 countries, including in an offshoring delivery centre in Morocco, with 850 employees. SQLI's core market continues to grow and the company is recognized for its strong technical capabilities and track record. SQLI's client base includes multinational blue-chip corporates such as: Nestle, Airbus, LVMH, Miele, L'Oreal, Richemont, Rolex, Carlsberg and many others.

Β 

Q1 Highlights

Β· In Q1 2025, DBAY and the SQLI management team launched a series of workstreams aimed at enhancing the business's positioning and profitability. These include the development of a rebranding initiative, scheduled to be rolled out after the summer, and operational improvements.

Β· Despite a subdued market environment, SQLI's Q1 financial results were in line with expectations. Revenue increased by approximately 2% on a like-for-like basis and at constant currency, outperforming peers in the French and international markets.

Β 

Β 

Alliance Pharma plc ("Alliance")

Business description

Alliance is a global healthcare platform that markets and distributes leading OTC consumer healthcare and prescription products. Alliance's portfolio is focused on damaged skin and healthy ageing, with its products sold globally, via the retail channel (Boots, Walgreens, etc.), pharmacies, and increasingly via e-commerce. the business has over 290 employees and is headquartered in Chippenham, Wiltshire.

Β 

Q1 Highlights

Β· Alliance's results for the year ended 31 December 2024 (being the last audited period) were broadly in line with expectations, with revenues falling 1% year-on-year to Β£180.3m (up 1% on constant exchange rate); the decline therefore driven by foreign exchange. Revenue at year end was marginally impacted by order delays, particularly for Nizoral in Q4 2024.

Β· In Q1 2025, DBAY successfully completed the take-private of Alliance Pharma plc. On 10 January 2025, DBAY announced a recommended offer to acquire the remaining shares at 62.50p per share. Following discussions with key shareholders on 10 March 2025, the offer was increased to a final price of 64.75p. This revised offer was approved via a Scheme of Arrangement which became effective on 14 May 2025.

Β 

This announcement contains inside information as defined in Article 7 of the EU Market Abuse Regulation Noβ€―596/2014, as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, and has been announced in accordance with the Company's obligations under Article 17 of that Regulation.

Β 

For enquiries:

Β 

Logistics Development Group plc

Via FTI Consulting

FTI Consulting

Nick Hasell

Alex Le May

+44 (0) 20 3727 1340

Β 

Β 

Strand Hanson Limited

(Financial and Nominated Adviser)

James Dance

Richard Johnson

Abigail Wennington

Β 

+44 (0) 20 7409 3494

Investec Bank plc

(Broker)

Gary Clarence

Harry Hargreaves

+44 (0) 20 7597 5970

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
PFUPPUUCAUPAGBB
Date   Source Headline
14th Jan 20229:05 amRNSSecond Price Monitoring Extn
14th Jan 20229:00 amRNSPrice Monitoring Extension
14th Jan 20227:00 amRNSPublication of Circular & Notice of GM
9th Dec 20217:00 amRNSDirectorate Changes
8th Nov 20219:00 amRNSReceipt of further cash payment
17th Sep 202110:47 amRNSHolding(s) in Company
23rd Aug 20214:51 pmRNSHolding(s) in Company
20th Aug 20217:00 amRNSInterim Results for six months ended 31 May 2021
17th Aug 20212:05 pmRNSSecond Price Monitoring Extn
17th Aug 20212:00 pmRNSPrice Monitoring Extension
6th Aug 20219:55 amRNSHolding(s) in Company
29th Jul 202111:26 amRNSHolding(s) in Company
29th Jul 202111:17 amRNSChange of Registered Office
15th Jul 20218:33 amRNSHolding(s) in Company
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 202111:00 amRNSPrice Monitoring Extension
1st Jul 20219:05 amRNSSecond Price Monitoring Extn
1st Jul 20219:00 amRNSPrice Monitoring Extension
1st Jul 20217:00 amRNSDisposal of Greenwhitestar Acquisitions
28th Jun 202111:05 amRNSSecond Price Monitoring Extn
28th Jun 202111:00 amRNSPrice Monitoring Extension
18th Jun 20212:32 pmRNSChange of Nominated & Financial Adviser & Broker
8th Jun 20214:41 pmRNSSecond Price Monitoring Extn
8th Jun 20214:35 pmRNSPrice Monitoring Extension
25th May 202112:43 pmRNSResult of AGM
6th May 20217:00 amRNSInvestment in PIK Loan
28th Apr 20211:30 pmRNSPosting of Annual Report & Notice of AGM
27th Apr 20217:00 amRNSHolding(s) in Company
13th Apr 20214:57 pmRNSHolding(s) in Company
1st Apr 202111:06 amRNSSecond Price Monitoring Extn
1st Apr 202111:00 amRNSPrice Monitoring Extension
1st Apr 20217:00 amRNSDirectorate Change
31st Mar 20214:41 pmRNSSecond Price Monitoring Extn
31st Mar 20214:35 pmRNSPrice Monitoring Extension
30th Mar 202112:00 pmRNSFinal Results for year ended 30 November 2020
20th Feb 20078:00 amRNSNomad and Broker Resignation
8th Feb 20077:01 amRNSFurther re: Suspension
31st Jan 20074:39 pmRNSStatement re. Suspension
30th Jan 20075:15 pmRNSDirectorate Change
8th Dec 20067:30 amRNSSuspension - Legacy Distribut
8th Dec 20067:30 amRNSStatement re. Suspension
13th Nov 20069:21 amRNSIssue of Equity
28th Sep 20067:05 amRNSInterim Results
9th Aug 20067:01 amRNSContract Extensions
12th Jun 20067:01 amRNSDirectorate Change
5th Jun 20067:01 amRNSFinal Results
21st Apr 20061:12 pmRNSDirectorate Change
3rd Apr 20067:02 amRNSContract Win
16th Mar 20067:44 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.